Stockscreener 앱 받기
33.07
0.30%
-0.10
시간 외 거래:
33.07
Cogent Biosciences Inc 주식(COGT)의 최신 뉴스
Stifel reiterates Cogent stock Buy rating after trial data - Investing.com UK
Stifel reiterates Cogent stock Buy rating after trial data By Investing.com - Investing.com India
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) - Seeking Alpha
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial - Moomoo
Cogent Biosciences unveils pivotal APEX trial data at EHA 2026 - grafa.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association Congress - Investing News Network
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association Congress - Investing News Network
Cogent Gallops on Data Release - Baystreet.ca
Cogent unveils positive preclinical data for JAK2 inhibitor CGT1145 - grafa.com
Experimental JAK2 inhibitor targets mutation in most polycythemia vera cases - Stock Titan
Cogent Biosciences Announces Detailed Data from Apex Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Director for Cogent Biosciences (NASDAQ: COGT) granted 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike - Stock Titan
Cogent Biosciences (COGT) director linked to option grant for funds - Stock Titan
Director at Cogent Biosciences (NASDAQ: COGT) receives 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director Arlene Morris receives grant of 17,901 stock options - Stock Titan
Cogent Biosciences (NASDAQ: COGT) 2026 meeting backs board, auditor and pay - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen - Yahoo Finance
Cogent Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Insider Monkey
Cogent Biosciences (COGT) Is Down 7.3% After Priority Review Win For Bezuclastinib Combo In GISTHas The Bull Case Changed? - Sahm
COGT News | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT) - The Globe and Mail
Assessing Cogent Biosciences (COGT) Valuation After PEAK Phase 3 Success And FDA Priority Review - Sahm
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Medline (MDLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR) - The Globe and Mail
COGT Technical Analysis & Stock Price Forecast - Intellectia AI
Stifel reiterates Cogent stock Buy rating on GIST drug data - Investing.com UK
Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Stifel reiterates Cogent stock Buy rating on GIST drug data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Cogent stock rating on trial results By Investing.com - Investing.com Australia
Cogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug. - MSN
UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Cogent Biosciences (COGT) Reveals Promising Phase 3 Trial Results for Bezuclastinib - GuruFocus
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors at 2026 American Society of Clinical Oncology Annual Meeting - Investing News Network
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK) - The Globe and Mail
Cogent Biosciences presented detailed clinical data from its PEAK Phase III trial at the 2026 American Society of Clinical Oncology Annual Meeting. - Bitget
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of... - markets.businessinsider.com
Cogent Biosciences announces detailed clinical data from peak phase 3 trial with bezuclastinib in combination with sunitinib - marketscreener.com
Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib - TradingView
Drug combo lets GIST patients go 16.5 months before tumors worsen - Stock Titan
Cogent Biosciences Company Profile & Introduction - Moomoo
Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
COGT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COGT Reiterates by Wedbush -- Price Target Maintained at $55 - GuruFocus
HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation - MSN
Cogent Biosciences (COGT) Receives FDA Acceptance for New Drug A - GuruFocus
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference - Sahm
Cogent Biosciences Announces FDA Acceptance of New Drug Application with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST - Investing News Network
Cogent Bio granted FDA priority review for lead asset in tumor indication - Seeking Alpha
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST - The Manila Times
(COGT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Cancer drug combo halves disease progression risk in GIST trial - Stock Titan
Six new Cogent Biosciences hires get stock options and RSUs - Stock Titan
Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback - Yahoo Finance
Cogent Biosciences Inc. Q1 2026 Earnings: Wider Loss but Stock Edges HigherTrough Earnings Signal - thelegaladvocate.com
Why is Cogent Biosciences stock up 4% today? By Investing.com - Investing.com Canada
Why is Cogent Biosciences stock up 4% today? - Investing.com
COGT Stock Chart | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
1.27%
1.43%
자본화:
|
볼륨(24시간):